On February 10, 2021 ENTEROME SA, a clinical-stage biopharmaceutical company focused on the discovery and development of novel microbiome driven therapeutics based on the unrivalled understanding of the gut microbiome’s interaction with the human immune system, reported that the company’s management will participate in the upcoming (virtual) investor events (Press release, Enterome, FEB 10, 2021, View Source;utm_medium=rss&utm_campaign=enterome-presenting-at-upcoming-investor-meetings [SID1234574854]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Chardan Virtual Microbiome Medicines Summit: March 8
H.C. Wainwright Global Life Sciences Conference: March 9-10
Pierre Belichard, Enterome’s CEO, will present the Company and take part in 1-on-1 meetings with institutional investors.

Mr Belichard will also take part in a panel discussion on the Microbiome & Cancer at:

USF Microbiome Virtual Corporate Forum Series, a free-to-register event (click here), on March 10 from 10:00-12:00 EST.

On February 10, 2021 Bio-Techne Corporation (NASDAQ: TECH) reported that Chuck Kummeth, President and Chief Executive Officer, will present at the 2021 SVB Leerink Global Healthcare Conference on Wednesday, February 24, 2021 at 11:20 a.m. EST (Press release, Bio-Techne, FEB 10, 2021, View Source [SID1234574853]). A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne’s Investor Relations website at View Source

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On February 10, 2021 Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, reported that management will participate in a virtual fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference on Thursday, February 25, 2021 at 8:00 a.m. ET (Press release, Aclaris Therapeutics, FEB 10, 2021, View Source [SID1234574852]). Management will be available February 25th throughout the day for virtual one-on-one meetings.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the fireside chat may be accessed through the "Events" page of the "Investors" section of Aclaris’ website, www.aclaristx.com. The webcast will be archived for at least 30 days on the Aclaris website.

On February 10, 2021 ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, reported that Chief Executive Officer, Gil Beyen, will present a corporate overview at the 2021 BIO CEO & Investor Conference and participate in select one-on-one investor meetings (Press release, ERYtech Pharma, FEB 10, 2021, View Source [SID1234574850]). The conference will be held virtually this year with all participants joining remotely from February 16 to 18, 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On February 10, 2021 Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, reported that management will participate in five upcoming virtual investor conferences (Press release, Zymeworks, FEB 10, 2021, View Source [SID1234574849]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Guggenheim Healthcare Talks Oncology Days, February 11-12, 2021. Zymeworks will be participating in the event; there is no public presentation.
SVB Leerink’s 10th Annual Global Healthcare Conference,February 22-26, 2021. Zymeworks will be participating in the conference, there is no public presentation.
Raymond James’ 42nd Annual Institutional Investor Conference, March 1-3, 2021. Zymeworks will be participating in the conference; there is no public presentation.
Barclays’ Global Healthcare Conference, March 9-11, 2021. Zymeworks is presenting on Thursday, March 11, 2021 at 1:15 p.m. ET.
Citi’s 2021 Winter West Coast Biotech Virtual Bus Tour, March 16-17, 2021. Zymeworks will be participating in the event; there is no public presentation.
Interested parties can access a live webcast of the Barclays presentation via a link from Zymeworks’ website at View Source, which will also host a recorded replay available afterwards.